As the number of cases of COVD-19 continues to rise, the mainstay therapy for those with mild to moderate symptoms of COVID-19 remains to be supportive therapy, which includes use of analgesics such as ibuprofen.
Recent reports of a potential harm with ibuprofen in patients with COVID-19 has received significant international media coverage. The news started when an infectious disease specialist in France anecdotally reported four cases of children who took ibuprofen and experienced worsening symptoms of COVID-19 infection in her clinic 1 . This opinion was soon endorsed by the French Health Minister and the World Health Organization (WHO) 1,2 . Other professional entities including the National Health Services and the British Pharmacological Society have taken a more balanced tone suggesting that patients use acetaminophen as the first drug of choice until more evidence is collected 1 . The WHO has now retracted their earlier warning against using ibuprofen 3 .
Given this issue will be in the minds of many for the near future, clinicians need to have a picture of both the strength and quality of the evidence before they can make informed decisions regarding use of ibuprofen for COVID-19 patients.
Evidence on the safety of Ibuprofen in COVID-19 patients
The evidence behind this controversy comes anecdotally from an infectious diseases specialist in France who reported four cases of worsening symptoms of COVID-19 1 , which we could not identify in the published literature. The second source was a letter written by Fang et al. where they claimed that ibuprofen may worsen associated symptoms in those infected with COVID-19 4 . They argued that coronaviruses bind to angiotensin-converting enzyme-2 (ACE-2), and ibuprofen administration can increase the bioavailability of ACE-2, thus potentiating and enhancing the infectious processes of coronaviruses 4 .
One needs to be cautious on drawing conclusions from evidence that is derived from mechanistic or theoretical pharmacology. There are a number of examples in the literature where evidence from mechanistic studies is not always corroborated with data from clinical trials. For example, some studies have shown that co-administration of ibuprofen with aspirin can counteract the anti-platelet effectiveness of aspirin when thromboxane levels where measured 5 . This hypothesis, however, was refuted in a large randomized clinical trial 6 .
Evidence on the safety of Ibuprofen in Respiratory Infections
Other investigators 7 have also advocated to not use ibuprofen based on previous studies that have shown negative outcomes among ibuprofen users. For example, a database study from France found that patients who had prehospitalization use of NSAIDs for symptoms of community acquired pneumonia developed more severe pneumonia and stayed hospitalized longer than nonusers 8 . Another study examined risk factors for complicated community acquired infection in children 9 . Both ibuprofen (odds ratio (OR)=3.27, 95% CI:1.11-9.65) and acetaminophen (OR=2.68, 95%CI: 1.37-5.23) were identified as risk factors 9 .
Epidemiologic studies that have identified ibuprofen with negative respiratory outcomes are subject to a number of biases. These biases include protopathic bias, where ibuprofen is used to relieve symptoms of a viral infection, including COVID-19, making it seem like ibuprofen is the culprit. Confounding by disease severity (also referred to as channeling bias) should also be considered in many of these studies, especially those which compared this risk to non-users.
Patients with more severe viral infections including the flu or COVID-19 are more likely to use a stronger anti-inflammatory drug such as ibuprofen than acetaminophen. Thus, a potential harmful outcome is more likely to be due to a more severe infection for which ibuprofen is prescribed, rather than the drug.
Where do we go from here?
Since a randomized trial would not be suitable to answer this question, a large population based observational cohort or case-control study might be the ideal study design that can answer this question. However, having the ideal data source might be a challenge for this study as it needs to adequately address confounding, especially confounding by disease severity as well as measurement error (also referred to as misclassification of exposure) as many people use ibuprofen over the counter in addition to prescription medication.
In summary, the current epidemiological evidence is not strong enough to infer a causal link of a harmful effect of ibuprofen in patients with COVID-19. Evidence from mechanistic studies alone should not be used to make strong statements against use of ibuprofen. Given the current strength of the evidence on this topic, we advise that patients use acetaminophen monotherapy for fever reduction in a patient with COVID-19, as per WHO recommendations 3 . If acetaminophen alone cannot achieve its antipyretic effect, the current evidence is not sufficient to advise against coadministration of ibuprofen with acetaminophen, although risk of adding ibuprofen should still be assessed against its benefits.
